BR112017005421A2 - método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfr - Google Patents
método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfrInfo
- Publication number
- BR112017005421A2 BR112017005421A2 BR112017005421A BR112017005421A BR112017005421A2 BR 112017005421 A2 BR112017005421 A2 BR 112017005421A2 BR 112017005421 A BR112017005421 A BR 112017005421A BR 112017005421 A BR112017005421 A BR 112017005421A BR 112017005421 A2 BR112017005421 A2 BR 112017005421A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitor
- react
- cancer patients
- egfr
- kit
- Prior art date
Links
- 108060006698 EGF receptor Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 title 1
- 108091006082 receptor inhibitors Proteins 0.000 title 1
- 229940121647 egfr inhibitor Drugs 0.000 abstract 3
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108091070395 Homo sapiens miR-31 stem-loop Proteins 0.000 abstract 1
- 230000002596 correlated effect Effects 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 108091070501 miRNA Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14306490.5A EP3000895A1 (en) | 2014-09-26 | 2014-09-26 | A method for predicting responsiveness to a treatment with an EGFR inhibitor |
| PCT/EP2015/072095 WO2016046365A1 (en) | 2014-09-26 | 2015-09-25 | A method for predicting responsiveness to a treatment with an egfr inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017005421A2 true BR112017005421A2 (pt) | 2017-12-12 |
Family
ID=51663116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017005421A BR112017005421A2 (pt) | 2014-09-26 | 2015-09-25 | método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfr |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20170298442A1 (enExample) |
| EP (2) | EP3000895A1 (enExample) |
| JP (1) | JP2017529852A (enExample) |
| KR (1) | KR20170086469A (enExample) |
| CN (1) | CN107075583A (enExample) |
| AU (1) | AU2015323744A1 (enExample) |
| BR (1) | BR112017005421A2 (enExample) |
| CA (1) | CA2961434A1 (enExample) |
| MX (1) | MX2017003832A (enExample) |
| WO (1) | WO2016046365A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10400288B2 (en) | 2015-02-11 | 2019-09-03 | Aarhus Universitet | MicroRNA-based method for early detection of prostate cancer in urine samples |
| JP6769979B2 (ja) * | 2015-02-27 | 2020-10-14 | キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング | マイクロｒｎａに基づく前立腺がん患者の予後評価方法 |
| CN108034727B (zh) * | 2018-01-18 | 2021-05-28 | 四川大学华西医院 | 检测MicroRNA-31-5p表达水平的试剂在制备肿瘤靶向药敏感性检测试剂盒中的用途 |
| KR102480430B1 (ko) * | 2020-10-21 | 2022-12-21 | 순천향대학교 산학협력단 | 주사증 진단을 위한 마이크로RNA-31-5p 및 이의 용도 |
| CN119303090B (zh) * | 2024-10-15 | 2025-06-20 | 中国医学科学院北京协和医院 | miR-210-3p和/或miR-31-5p在薄型子宫内膜中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101663B2 (en) | 2001-03-02 | 2006-09-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | PCR method |
| WO2009080437A1 (en) | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| WO2010121238A2 (en) | 2009-04-17 | 2010-10-21 | Translational Genomics Research Institute (Tgen) | Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors |
| CN105177119A (zh) * | 2009-06-19 | 2015-12-23 | 默克专利有限公司 | 用于测定抗egfr抗体在癌症治疗中的功效的生物标记和方法 |
| WO2011135459A2 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
| JP6342329B2 (ja) | 2011-11-25 | 2018-06-13 | アンテグラジャンＩｎｔｅｇｒａｇｅｎ | Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法 |
| CN104046679B (zh) * | 2013-03-11 | 2016-08-24 | 戴勇 | 原发性IgA肾病肾脏组织差异表达miRNA的分析方法和应用 |
-
2014
- 2014-09-26 EP EP14306490.5A patent/EP3000895A1/en not_active Withdrawn
-
2015
- 2015-09-25 KR KR1020177009944A patent/KR20170086469A/ko not_active Withdrawn
- 2015-09-25 AU AU2015323744A patent/AU2015323744A1/en not_active Abandoned
- 2015-09-25 MX MX2017003832A patent/MX2017003832A/es unknown
- 2015-09-25 EP EP15767530.7A patent/EP3198028B1/en not_active Not-in-force
- 2015-09-25 BR BR112017005421A patent/BR112017005421A2/pt not_active IP Right Cessation
- 2015-09-25 WO PCT/EP2015/072095 patent/WO2016046365A1/en not_active Ceased
- 2015-09-25 US US15/513,223 patent/US20170298442A1/en not_active Abandoned
- 2015-09-25 JP JP2017516368A patent/JP2017529852A/ja not_active Withdrawn
- 2015-09-25 CN CN201580051832.9A patent/CN107075583A/zh active Pending
- 2015-09-25 CA CA2961434A patent/CA2961434A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015323744A1 (en) | 2017-04-27 |
| CN107075583A (zh) | 2017-08-18 |
| EP3198028B1 (en) | 2018-12-12 |
| JP2017529852A (ja) | 2017-10-12 |
| MX2017003832A (es) | 2018-02-23 |
| US20170298442A1 (en) | 2017-10-19 |
| CA2961434A1 (en) | 2016-03-31 |
| WO2016046365A1 (en) | 2016-03-31 |
| EP3000895A1 (en) | 2016-03-30 |
| EP3198028A1 (en) | 2017-08-02 |
| KR20170086469A (ko) | 2017-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018069849A2 (pt) | kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático | |
| BR112016029583A2 (pt) | ?kit ou dispositivo para a detecção de câncer esofágico e método de detecção? | |
| MX2017008421A (es) | Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga. | |
| MX2019007814A (es) | Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata. | |
| BR112016002845A2 (pt) | composições e métodos para tratar condições associadas ao complemento | |
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| BR112013030606A2 (pt) | biomarcadores para terapia inibidora de hedgehog | |
| BR112016029634A2 (pt) | kit, dispositivo e método para a detecção de câncer de fígado | |
| BR112017005421A2 (pt) | método in vitro para prever se pacientes com câncer são propensos a reagir a um inibidor de receptor, kit e inibidor de egfr | |
| BR112016028944A2 (pt) | kit ou dispositivo para a detecção de câncer do trato biliar e método de detecção | |
| BR112016019740A2 (pt) | monitoramento do estado de inflamação | |
| MX2014006182A (es) | Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. | |
| MX2017000840A (es) | Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer. | |
| BR112018008799A2 (pt) | método de prognóstico | |
| BR112012007555A2 (pt) | biomarcadores para prever a sensibilidade e resposta de doenças mediadas por quinase de proteína ck2 a inibidores de ck2 | |
| BR112016012001A2 (pt) | método in vitro de previsão se um paciente com câncer é propenso a reagir a um inibidor, kit, inibidor de egfr e método de tratamento de paciente afetado com câncer | |
| BR112016017926A2 (pt) | ensaio para detectar periostina humana | |
| ES2530743T3 (es) | Método in vitro y kit para el pronóstico o predicción de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor TNFalfa | |
| BR112015019425A2 (pt) | Métodos e kits para identificar e ajustar desvio no sequenciamento de amostras de polinucleotídeos | |
| BR112019001446A2 (pt) | edição de rna como biomarcadores para teste de transtornos de humor | |
| WO2015115923A3 (en) | A profile of microrna in the blood as a test for the detection of lung cancer | |
| BR112018071395A2 (pt) | métodos de identificação de pacientes, método de previsão do risco de progressão para lvh, método de diferenciação em pacientes, métodos de previsão se pacientes se encontram com risco de progressão para lvh e uso | |
| BR112018010848A2 (pt) | grelin-o-acilotransferase (cabra) e usos da mesma | |
| UA106708U (uk) | Спосіб прогнозування зрощення перелому |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2599 DE 27-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |